Back to search page

TODE20200302001

Mas-related gene X2 receptor antagonists

TECHNOLOGY PROFILE   OFFER   ADD TO FAVOURITES

 

ABSTRACT

A German university offers a new drug target for inflammatory and other diseases related to the mas-related gene X2 (MRGX2) receptor. It will find application in treating pain conditions that involve mast cells, such as skin itching and pain. Related illnesses may be included. Industrial partners are sought for license agreements.

 

FULL DESCRIPTION

G protein-coupled receptors (GPCRs) are the largest group of membrane receptor proteins and represent the most successful targets of drug therapy. The MRGPRX (mas-related G protein-coupled receptor X) subfamily is only expressed in primates including humans and belongs to the group of orphan receptors, for which the cognate agonists are unknown. The MRGX2 receptor subtype exhibits unique features that distinguish it from other GPCRs. It is involved in mast cell degranulation, nociception and itching, and represents a fundamentally new drug target. Relating thereto, the development of potent and selective MRGPRX2 receptor antagonists is a basic need for the design of anti-nociceptive or anti-pruritic drugs or for the prevention or treatment of other diseases like inflammatory diseases, non-allergic hypersensitivity reactions, fibrosis (lung, liver etc.) or neuropathic pain.

A German university offers an invention that relates to a method for preventing or treating a disease or disorder that is associated with the MRGX2 receptor. The technology embodies potent and selective MRGX2 receptor antagonists, including G protein-biased antagonists, that may especially be used for treating pain conditions, such as neuropathic or chronic pain and itch, and reactions, e.g. of the skin, in which mast cells are involved. Many related illnesses may be included, e.g. stress-associated syndromes or asthma, urticaria, skin inflammation, dry skin, psoriasis etc. Given the newly elucidated role of this receptor in chronic urticaria and pseudoallergic reactions, the antagonists have a high potential to be used for target validation, for preclinical studies, and for their clinical development of novel drugs.

Industrial partners, interested in developing new drugs are sought for license agreements.


Partner expertise sought:

- Specific area of activity of the partner: The university offers licenses for the invention to interested companies from pharmaceutical industry. Within the agreement there is also the possibility of collaboration with the inventors, e.g. in preclinical studies, joint drug development and tests.


Advantages & innovations:

Completely new drug target for more effective treatment of several diseases, e.g.
Pain (e.g. neuropathic, inflammatory)
Itching
Pruritus
Skin inflammation
Non-allergic hypersensitivity
Asthma
Fibrosis


Development Stage:

Under development/lab tested - In vitro characterization in recombinant cells and on native human mast cells.


IPR:

Patent(s) applied for but not yet granted - US patent applied for

Sign-in or create an account

To express an interest in this profile, you must first sign in or create a new account.

If you already have an account, sign in here

Not got an account yet, sign up here

KEY INFORMATION

Country of origin
GERMANY
Date created
02/03/2020
Date updated
26/02/2021
Deadline
08/09/2021

PARTNERSHIP(S) SOUGHT

License agreement

CLASSIFICATIONS

INDUSTRY SECTORS
Other Industrial Technologies \ Medicine and Health \ Life Sciences \ Chemistry & Chemical Engineering \ Big drug delivery client
TECHNOLOGY KEYWORDS
OTHER INDUSTRIAL TECHNOLOGIES / Chemical Technology and Engineering / Pharmaceutics / BIOLOGICAL SCIENCES / Medicine, Human Health / Gene - DNA Therapy / BIOLOGICAL SCIENCES / Medicine, Human Health / Pharmaceutical Products / Drugs
COMMERCIAL KEYWORDS
none...
MARKET KEYWORDS
MEDICAL/HEALTH RELATED / Therapeutic / Therapeutic services / MEDICAL/HEALTH RELATED / Other Medical/Health Related / Pharmaceuticals/fine chemicals
A2020